MRD in Hematologic Malignancies: Testing Considerations and Challenges

MRD in Hematologic Malignancies: Testing Considerations and Challenges

On-Demand Webcast

Gail J. Roboz, MD
Weill Cornell Medicine
New York, New York


Ajai Chari, MD
The Mount Sinai Hospital
New York, New York

Steven Coutre, MD
Stanford University Medical Center
Stanford, California

Prashant Kapoor, MD
Mayo Clinic
Rochester, Minnesota

Aaron C. Logan, MD, PhD
University of California, San Francisco
San Francisco, California

Target Audience

This activity is intended for hematologists, oncologists, PAs, NPs, nurses, pharmacists, and pathologists who specialize in hematology, as well as other HCPs who care for patients with hematologic malignancies.


Although systemic targeted agents have led to higher rates of progression-free survival (PFS), overall survival (OS), and complete remission (CR) in hematologic malignancies, residual disease continues to remain undetected, and CR is often not sustained. As measurable residual disease (MRD), also referred to as minimal residual disease, defined as the presence of residual disease at very low levels, is the primary cause of all relapses, interest in MRD measurement as a prognostic factor has increased over the past decade. Sensitive and specific measurement of MRD has the potential to significantly affect relapse rates and personalize treatment decision-making, thereby improving disease outcomes. However, the real-world application of MRD to clinical practice is unclear, and clinicians wishing to utilize new technologies are left with a myriad of questions regarding which test to use, how to test, when to test, in whom to test, and how to interpret results. Therefore, to reach providers positioned to effect meaningful change within the management of hematologic malignancies and positively impact patient care, education that centers on the latest MRD evidence and the clinical implications of MRD testing is warranted and necessary.

This program aims to address MRD-related knowledge and practice gaps among clinicians who manage patients with hematologic malignancies, as well as scientists and pathologists dedicated to disease management and research.


Upon successful completion of this educational activity, participants should be better able to:

  1. Compare currently available MRD testing methods and describe their application to discrete hematologic malignancies
  2. Discuss existing guideline recommendations for MRD testing and the various factors that may affect MRD test results
  3. Evaluate the prognostic significance of MRD across the spectrum of hematologic malignancies
  4. Describe potential future applications for MRD in real-world clinical practice, including the significance of MRD in clinical trials and agent development

Release Date: January 22, 2020

Expiration Date: January 22, 2021

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Supported by educational grants from: Adaptive Biotechnologies and Sanofi Genzyme. 


 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 


NACCME designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 3.5 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 3.5 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 3.5 contact hours.


This knowledge-based activity (JA0006201-9999-20-076-H01-P) is approved for 3.5 contact hours (0.35 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Ajai Chari, MD, Steven Coutre, MD, Prashant Kapoor, MD, Aaron C. Logan, MD, PhD, Gail Roboz, MD; and Chris Bolwell, and Griselda Zuccarino-Catania, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Ajai Chari, MD, reports that he has nothing to disclose in relation to this activity.

Steven Coutre, MD, reports that he has a consultancy relationship with AbbVie, Astellas, AstraZeneca, Celgene, Genentech, Janssen, and Pharmacyclics; has received honoraria from Janssen and Pharmacyclics; has had membership on a board of directors or advisory committee for AbbVie, Astellas, AstraZeneca, Celgene, Genentech, Janssen, and Pharmacyclics; has
recevied research funding from AbbVie, Acerta, Celgene, Gilead, and Janssen; has served on the data safety monitoring committee for BeiGene; and has received travel, accommodations, or other expesnes from AbbVie, BeiGene, Celgene, Janssen, and Pharmacyclics.

Prashant Kapoor, MD, reports that he has recevied research funding from Celgene, GlaxoSmithKline, Sanofi, and Takeda; and has received honoraria from Celgene and Takeda.

Aaron C. Logan, MD, PhD, reports that he has had membership on a board of directors or advisory committee for Agios, Amgen, and Incyte.

Gail Roboz, MD, reports that she has a consultancy relationship with AbbVie, Actinium, Amphivena, Argenx, Astellas, Astex, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Janssen, Jazz, MEI Pharma, Novartis, Orsenix, Otsuka, Pfizer, Roche/ Genentech, Sandoz, and Takeda; and has received research funding from Cellectis.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.